• 

  Could Alzheimer’s Drugs Work Better in Pairs? A New Approach for ‘Mabs’
• 

  4 Big Questions About New Alzheimer’s Anti-Amyloid Drugs, Answered
• 

  How Safe Is Alzheimer’s Drug Leqembi — and Who’s Taking It?
• 

  Everything You Wanted to Know About ARIA
• 

  Alzheimer’s Anti-Amyloids Haven’t Wowed—What If They Were Administered Years Earlier?
• 

  Trojan Horse: Carrying Alzheimer’s Antibodies Into the Brain
• 

  No Kisunla in Europe: Regulators Reject Lilly’s Alzheimer’s ‘Mab’ Drug
• 

  Remternetug: Alzheimer’s Prevention Trial Enrolls People as Young as 18
• 

  ‘Mission Critical’: Why the FDA Approved an Alzheimer’s Drug Update During Comms Freeze
• 

  Some Trial Volunteers Had Higher Risk of Brain Bleeds. Here’s Why Drugmakers Didn’t Tell Them
• 

  CTAD: Leqembi’s Origin Story, 30 Years Ago in Arctic Sweden
• 

  A Pill to Slow Down Alzheimer’s Is as Little as a Year Away
• 

  Alzheimer’s Rates Are Highest In These Counties—But No Leqembi Access
• 

  Alzheimer’s Drug Decision Pushed: FDA Slows Down on Donanemab
• 

  Leading Neurologist: This Gene Raises Your Risk of Alzheimer’s—and Drug Side Effects

12Next